Navigation Links
Scripps Research announces research & license agreement with Janssen Pharmaceuticals
Date:5/7/2013

LA JOLLA, CA May 7, 2013 The Scripps Research Institute (TSRI) today announced a five-year agreement with Janssen Pharmaceuticals, Inc. (Janssen) to collaborate on focused research projects in the infectious disease area, with the initial project targeting the influenza virus. Under the agreement Janssen will receive certain license rights to the results of the research. Janssen Pharmaceuticals will collaborate in the research on influenza through its Crucell Vaccine Institute.

"We're delighted to partner with Janssen in this work that could have a significant impact on human health," said Michael A. Marletta, president and CEO of TSRI. "The new agreement leverages the institute's significant strengths in structural biology to move forward new therapies and vaccines."

Scott Forrest, TSRI's vice president for business development, added, "This deal is the latest example of our corporate partnership strategy, in which we seek focused collaborations to match companies' specific areas of interest with areas of expertise among multiple TSRI labs."

The new agreement builds on research on the influenza virus conducted jointly by TSRI and Janssen's Crucell Vaccine Institute. Previous collaborations have resulted in several high-impact publications, most recently in August 2012 in the journal Science.

Seasonal flu typically causes more than 200,000 hospitalizations and 36,000 deaths every year in the United States, according to estimates by the U.S. Centers for Disease Control. Pandemics pose a greater dangerthe Spanish Flu of 1918-1919 may have killed 50 million people worldwide.

The new strategic collaboration with Janssen follows TSRI's announcement of a five-year agreement with Bristol-Myers Squibb last June; that agreement covered the development of chemistry methodologies and related work.

Forrest notes that promising future areas for corporate partnerships at TSRI include Oncology, Neurodegeneration and Immunology.


'/>"/>

Contact: Mika Ono
mikaono@scripps.edu
858-784-2052
Scripps Research Institute
Source:Eurekalert

Related biology news :

1. Scripps Research discoveries lead to newly approved drug for infant respiratory distress syndrome
2. Scripps Research Institute scientists find promising vaccine targets on hepatitis C virus
3. Scripps Research Institute Professor Gerald F. Joyce elected to American Academy of Arts & Sciences
4. Scripps Research Institute scientists develop antidote for cocaine overdose
5. Scientist wins $3 million renewal of one of longest-running NIH grants to Scripps Research
6. Scripps research scientists find anticonvulsant drug helps marijuana smokers kick the habit
7. Scripps Florida scientist awarded $1.5 million to design therapeutics with new RNA approach
8. Scripps Florida scientists identify neurotranmitters that lead to forgetting
9. Plastic trash altering ocean habitats, Scripps study shows
10. Scripps Florida scientists awarded $8.4 million grant to develop new anti-smoking treatments
11. Esther B. OKeeffe Foundation gives $2 million to the Scripps Research Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/10/2020)... , ... March 10, 2020 , ... ... Cytonus’ Board of Directors. Dr. Narasimhan is Senior Vice President of Strategic Initiatives, ... of the Board of Directors of Cytonus, we are extremely pleased to welcome ...
(Date:3/5/2020)... DIEGO (PRWEB) , ... March ... ... today announces the formation of its Scientific Advisory Board (SAB) comprised of ... academic institutions, immune-oncology centers, cell therapy centers, and private industry. Cytonus is ...
(Date:3/5/2020)... ... 05, 2020 , ... In September 2016, stem cell biotechnology ... is the first, and still only, available technology that provides the cell-specific count ... information about the number and quality of therapeutic tissue stem cells are unable ...
Breaking Biology News(10 mins):
(Date:2/19/2020)... ... February 18, 2020 , ... Shoreline Biome, ... to the strain level, recently unveiled a novel DNA isolation product. , Shoreline ... isolation of high molecular weight (HMW) single-stranded DNA (ssDNA) in excess of 40 ...
(Date:2/19/2020)... ... February 19, 2020 , ... ... the life sciences industry, today announced the opening of a new office in ... Red Nucleus R&D. , Red Nucleus announced the new office in response to ...
(Date:2/11/2020)... ... February 11, 2020 , ... ... successful results from a long-term follow-up clinical study of outpatient L4-L5 lumbar ... (INSPAN LLC). Unlike extension block design, the Inspan device fixates the spine ...
(Date:2/10/2020)... ... February 10, 2020 , ... R3 Medical Training announced it is now ... in Las Vegas. The course is hands on involving real patients and stem cell ... years, the Comprehensive Stem Cell Training Course has received rave reviews from attendees, who ...
Breaking Biology Technology: